ReviewCancer immunology, immunotherapy : CII2005
Immunoprevention and immunotherapy of cancer in ageing.
Review in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.Scientific reports · 2017Article
- Article
- Efficacy and Safety of Endoscopic Papillary Large Balloon Dilation for Removal of Large Bile Duct Stones in Advanced Age.Canadian journal of gastroenterology & hepatology · 2016Article
- Risk factors for malignancy in branched-type intraductal papillary mucinous neoplasms of the pancreas during the follow-up period.World journal of surgery · 2015Article
- Salivary Immunoglobulin A Secretion Rate Is Negatively Associated with Cancer Mortality: The West of Scotland Twenty-07 Study.PloS one · 2015Article
- Androgen receptor accelerates premature senescence of human dermal papilla cells in association with DNA damage.PloS one · 2013Article
- In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.Cancer immunology, immunotherapy : CII · 2012Article
- Immunosenescence and cancer vaccines.Cancer immunology, immunotherapy : CII · 2009Review
- Immunity, ageing and cancer.Immunity & ageing : I & A · 2008Article
- Effects of aging and dietary restriction on ubiquitination, sumoylation, and the proteasome in the spleen.FEBS letters · 2007Article
- Vaccination therapy in prostate cancer.Cancer immunology, immunotherapy : CII · 2007Review
- Immunosupportive therapies in aging.Clinical interventions in aging · 2007Review
- Immunosenescence, suppression and tumour progression.Cancer immunology, immunotherapy : CII · 2006Review
- Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.Gene therapy · 2005Article
- The impact of age on the incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last few years there has been a growing interest in geriatric oncology, mainly because of the evidence that advanced age is the greatest risk factor for the development of cancer and that, since the elderly population is rapidly expanding, so too will the number of cancer patients. This forecast necessitates the development of new and more specific strategies for the prevention and cure of cancer in the elderly and as a result an ever-increasing need for oncologists, geriatricians and researchers to work closely together. The increased incidence of cancer in elderly people has been related to the age-associated changes occurring in the immune system, the so-called immunosenescence. This phenomenon is best characterised by a remodelling of the immune system, which appears early on and progresses throughout a person's life and mainly involves a decrease in cellular functions. This review aims to provide a rationale for the development of specific immunotherapeutic and immunopreventive regimens for the elderly. We also include a discussion on the influence that immunosenescence has on the growth of tumours and the effectiveness of immunogene therapy and cancer vaccination following a brief analysis of the age-related alterations of the cell populations involved in antitumour immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.